🌟 #SyenzaNews: The landscape of Alzheimer’s treatment is evolving with new drugs on the horizon. While NICE recently found lecanemab’s benefits too small to justify its cost, promising treatments like donanemab, remternetug, and blarcamesine show potential. Learn more about these emerging therapies and their impact on Alzheimer’s care. 💊🧠
#AlzheimersResearch #HealthcareInnovation #PharmaNews #DementiaCare